Julie Adams, MD

Executive Director, Neuroscience Discovery Research
AbbVie

Poster(s):

• (270) Indirect treatment comparison of somnolence or sedation with dopamine partial agonists versus D2 receptor antagonists in major depressive disorder and schizophrenia
  Wednesday, October 29, 2025